Method for treating cancer using dengue virus serotype 1 (DENV-1)
AssigneePrime Vax Immuno-Oncology, Inc.
InventorBruce W. Lyday
Life of this patent
Estimating the term…
Abstract
Described herein are compositions and methods for treating a disease, particularly a cancer, with a Dengue Virus and, optionally, primed dendritic cells recognizing a tumor antigen. Lysis protocols are described where the lysis does not result in complete or less than complete lysis of cells in order to provide cell surface molecules maintained in a cell surface-embedded state. Non-lethal Dengue virus strains are also provided for therapeutic purposes.
Claims12
A method of treating a solid cancer, comprising administering to a solid cancer an effective amount of a Dengue virus serotype 1 strain, wherein the solid cancer is a melanoma, wherein the Dengue virus serotype 1 strain is 45AZ5, wherein the administering reduces a level of cancer cells, and wherein the Dengue virus serotype 1 strain is present in an amount up to about 90,000 PFU.
Dependencies are inferred from the claim text.